Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 454

1.

N2 year in review.

Dalmau J, Dalakas MC, Kolson DL, Paul F, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2019 Dec 12;7(1). pii: e644. doi: 10.1212/NXI.0000000000000644. Print 2020 Jan. No abstract available.

2.

Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice.

Dimitriadou MM, Alexopoulos H, Akrivou S, Gola E, Dalakas MC.

Neurotherapeutics. 2019 Oct 31. doi: 10.1007/s13311-019-00796-3. [Epub ahead of print]

PMID:
31673865
3.

Case 22-2019: A 65-Year-Old Woman with Myopathy.

Dalakas MC.

N Engl J Med. 2019 Oct 24;381(17):1693. doi: 10.1056/NEJMc1911058. No abstract available.

PMID:
31644862
4.

The immunobiology of autoimmune encephalitides.

Alexopoulos H, Dalakas MC.

J Autoimmun. 2019 Nov;104:102339. doi: 10.1016/j.jaut.2019.102339. Epub 2019 Oct 11. Review.

PMID:
31611142
5.

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis.

Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2019 Jun 10;6(4):e581. doi: 10.1212/NXI.0000000000000581. eCollection 2019 Jul.

6.

IVIG efficacy in CIDP patients is not associated with terminal complement inhibition.

Keller CW, Quast I, Dalakas MC, Lünemann JD.

J Neuroimmunol. 2019 May 15;330:23-27. doi: 10.1016/j.jneuroim.2019.02.001. Epub 2019 Feb 10.

PMID:
30772754
7.

Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder.

Rakocevic G, Alexopoulos H, Dalakas MC.

BMC Neurol. 2019 Jan 3;19(1):1. doi: 10.1186/s12883-018-1232-z.

8.

Immunotherapy in myasthenia gravis in the era of biologics.

Dalakas MC.

Nat Rev Neurol. 2019 Feb;15(2):113-124. doi: 10.1038/s41582-018-0110-z. Review.

PMID:
30573759
9.

Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system.

Dalakas MC.

Ther Adv Neurol Disord. 2018 Sep 14;11:1756286418799864. doi: 10.1177/1756286418799864. eCollection 2018. Review.

10.

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.

Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP; FORCIDP Trial Investigators.

Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9. Erratum in: Lancet Neurol. 2018 Nov;17(11):933.

11.

Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy.

Alexopoulos H, Akrivou S, Mastroyanni S, Antonopoulou M, Dinopoulos A, Giorgi M, Konstantinou K, Kouremenos E, Lariou M, Naoumis D, Pavlidou E, Pavlou E, Voudris K, Vlachoyiannopoulos P, Dalakas MC.

Ther Adv Neurol Disord. 2018 Apr 23;11:1756286418768778. doi: 10.1177/1756286418768778. eCollection 2018.

12.

Myositis: Are autoantibodies pathogenic in necrotizing myopathy?

Dalakas MC.

Nat Rev Rheumatol. 2018 May;14(5):251-252. doi: 10.1038/nrrheum.2018.54. Epub 2018 Apr 12. No abstract available.

PMID:
29651118
13.

Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy.

Rakocevic G, Martinez-Outschoorn U, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 5;5(4):e460. doi: 10.1212/NXI.0000000000000460. eCollection 2018 Jul. No abstract available.

14.

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.

Dalakas MC.

Ther Adv Neurol Disord. 2018 Jan 15;11:1756285617746640. doi: 10.1177/1756285617746640. eCollection 2018. Review.

15.

Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy.

Dalakas MC.

Lancet Neurol. 2018 Jan;17(1):20-21. doi: 10.1016/S1474-4422(17)30379-4. Epub 2017 Nov 6. No abstract available.

PMID:
29122522
16.

Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost.

Dalakas MC.

Ther Adv Neurol Disord. 2017 Aug;10(8):293-296. doi: 10.1177/1756285617717155. Epub 2017 Jun 28. No abstract available.

17.

A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.

Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B.

Ann Neurol. 2017 Aug;82(2):271-277. doi: 10.1002/ana.25002. Epub 2017 Aug 9.

18.

Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors.

Dalakas MC.

J Neurol Sci. 2017 Jun 15;377:224-226. doi: 10.1016/j.jns.2017.04.016. Epub 2017 Apr 13. No abstract available.

PMID:
28477700
19.

Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease.

Fouka P, Alexopoulos H, Chatzi I, Dedos SG, Samiotaki M, Panayotou G, Politis P, Tzioufas A, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 5;4(1):e306. eCollection 2017 Jan.

20.

Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business.

Dalakas MC.

Neurology. 2016 Jul 26;87(4):350-1. doi: 10.1212/WNL.0000000000002796. Epub 2016 Jun 29. No abstract available.

PMID:
27358340
21.

Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis.

Dalakas MC.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1037. doi: 10.1136/jnnp-2016-313418. Epub 2016 May 5. No abstract available.

PMID:
27151962
22.

Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J.

BMC Neurol. 2016 Apr 16;16:48. doi: 10.1186/s12883-016-0568-5.

23.

Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations.

Kampylafka EI, Alexopoulos H, Fouka P, Moutsopoulos HM, Dalakas MC, Tzioufas AG.

Lupus. 2016 Oct;25(11):1260-5. doi: 10.1177/0961203316636473. Epub 2016 Feb 27.

PMID:
26923281
24.

Close to the node but far enough: What nodal antibodies tell us about CIDP and its therapies.

Dalakas MC, Gooch C.

Neurology. 2016 Mar 1;86(9):796-7. doi: 10.1212/WNL.0000000000002427. Epub 2016 Feb 3. No abstract available.

PMID:
26843563
25.

Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab.

Magira EE, Alexopoulos H, Charitatos E, Michas D, Dalakas MC.

Ther Adv Neurol Disord. 2016 Jan;9(1):69-73. doi: 10.1177/1756285615614812. No abstract available.

26.

Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.

Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):1-3. doi: 10.1007/s13311-015-0414-2. No abstract available.

27.

Viruses in IBM: Hit-and-run, hide and persist, or irrelevant?

Dalakas MC, Schmidt J.

Neurology. 2016 Jan 19;86(3):204-5. doi: 10.1212/WNL.0000000000002295. Epub 2015 Dec 18. No abstract available.

PMID:
26683647
28.

Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease.

Alexopoulos H, Kampylafka EI, Fouka P, Tatouli I, Akrivou S, Politis PK, Moutsopoulos HM, Tzioufas AG, Dalakas MC.

J Neuroimmunol. 2015 Dec 15;289:8-11. doi: 10.1016/j.jneuroim.2015.10.007. Epub 2015 Oct 13.

PMID:
26616866
29.

Future perspectives in target-specific immunotherapies of myasthenia gravis.

Dalakas MC.

Ther Adv Neurol Disord. 2015 Nov;8(6):316-27. doi: 10.1177/1756285615605700. Review.

30.

Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Alexopoulos H, Biba A, Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):20-33. doi: 10.1007/s13311-015-0402-6. Review.

31.

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Kampylafka EI, Alexopoulos H, Dalakas MC, Tzioufas AG.

Neurotherapeutics. 2016 Jan;13(1):163-78. doi: 10.1007/s13311-015-0393-3. Review.

32.

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.

Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD.

J Clin Invest. 2015 Nov 2;125(11):4160-70. doi: 10.1172/JCI82695. Epub 2015 Oct 5.

33.

Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Lünemann JD, Quast I, Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):34-46. doi: 10.1007/s13311-015-0391-5. Review.

34.

Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4.

Kampylafka EI, Alexopoulos H, El Hamidieh A, Dalakas MC, Andreakos E, Tzioufas AG.

Autoimmunity. 2015;48(7):453-9. doi: 10.3109/08916934.2015.1070836. Epub 2015 Aug 14.

PMID:
26287441
35.

Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4.

Kampylafka EI, Alexopoulos H, El Hamidieh A, Dalakas MC, Andreakos E, Tzioufas AG.

Autoimmunity. 2015 Aug 14:1-7. [Epub ahead of print]

PMID:
26275078
36.

Inflammatory Muscle Diseases.

Dalakas MC.

N Engl J Med. 2015 Jul 23;373(4):393-4. doi: 10.1056/NEJMc1506827. No abstract available.

PMID:
26200989
37.

Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis.

Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 2;2(4):e131. doi: 10.1212/NXI.0000000000000131. eCollection 2015 Aug. No abstract available.

38.

HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis.

Muth IE, Zschüntzsch J, Kleinschnitz K, Wrede A, Gerhardt E, Balcarek P, Schreiber-Katz O, Zierz S, Dalakas MC, Voll RE, Schmidt J.

Exp Neurol. 2015 Sep;271:189-97. doi: 10.1016/j.expneurol.2015.05.023. Epub 2015 Jun 3.

PMID:
26048613
39.

Inflammatory muscle diseases.

Dalakas MC.

N Engl J Med. 2015 Apr 30;372(18):1734-47. doi: 10.1056/NEJMra1402225. Review. No abstract available.

PMID:
25923553
40.

GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.

Fouka P, Alexopoulos H, Akrivou S, Trohatou O, Politis PK, Dalakas MC.

J Neuroimmunol. 2015 Apr 15;281:73-7. doi: 10.1016/j.jneuroim.2015.03.009. Epub 2015 Mar 10.

PMID:
25867471
41.

Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.

Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, Van Doorn PA, Dalakas MC, Latov N.

Muscle Nerve. 2015 Oct;52(4):498-502. doi: 10.1002/mus.24624. Epub 2015 Jul 24.

PMID:
25728021
42.

Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

Stathopoulos P, Alexopoulos H, Dalakas MC.

Nat Rev Neurol. 2015 Mar;11(3):143-56. doi: 10.1038/nrneurol.2014.260. Epub 2015 Jan 27. Review.

PMID:
25623793
43.

Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Lünemann JD, Nimmerjahn F, Dalakas MC.

Nat Rev Neurol. 2015 Feb;11(2):80-9. doi: 10.1038/nrneurol.2014.253. Epub 2015 Jan 6. Review.

PMID:
25561275
44.

7th International Immunoglobulin Conference: Interlaken Leadership Awards.

Dalakas MC, Löscher WN.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:138. doi: 10.1111/cei.12544.

45.

7th International Immunoglobulin Conference: Interlaken Leadership Awards.

Dalakas MC, Löscher WN.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:124-6. doi: 10.1111/cei.12538.

46.

Autoimmune encephalitis with GABAB antibodies, thymoma, and GABAB receptor thymic expression.

Alexopoulos H, Dagklis IE, Akrivou S, Bostantjopoulou S, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e39. doi: 10.1212/NXI.0000000000000039. eCollection 2014 Dec. No abstract available.

47.

Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study.

Kosmidis ML, Koutsogeorgopoulou L, Alexopoulos H, Mamali I, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Tzioufas AG, Dalakas MC.

J Neurol Sci. 2014 Dec 15;347(1-2):143-7. doi: 10.1016/j.jns.2014.09.035. Epub 2014 Sep 28.

PMID:
25304055
48.

Reliability of the adult myopathy assessment tool in individuals with myositis.

Harris-Love MO, Joe G, Davenport TE, Koziol D, Abbett Rose K, Shrader JA, Vasconcelos OM, McElroy B, Dalakas MC.

Arthritis Care Res (Hoboken). 2015 Apr;67(4):563-70. doi: 10.1002/acr.22473.

49.

Lower extremity peak force and gait kinematics in individuals with inclusion body myositis.

Davenport TE, Benson K, Baker S, Gracey C, Rakocevic G, McElroy B, Dalakas M, Shrader JA, Harris-Love MO.

Arthritis Care Res (Hoboken). 2015 Jan;67(1):94-101. doi: 10.1002/acr.22468.

50.

Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase.

Markakis I, Alexopoulos H, Poulopoulou C, Akrivou S, Papathanasiou A, Katsiva V, Lyrakos G, Gekas G, Dalakas MC.

J Neurol Sci. 2014 Aug 15;343(1-2):192-4. doi: 10.1016/j.jns.2014.05.032. Epub 2014 May 27.

PMID:
24950904

Supplemental Content

Loading ...
Support Center